Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | OSBP | P22059 | 1/20 | 0.56 |
| ▸ | RORC | P51449 | 1/20 | 0.56 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.56 |
| ▸ | POLA1 | P09884 | 1/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 14/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 14/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 12/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4654756 | 0.89 | USP2 (0.59) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL18797660 | 0.87 | USP2 (0.58) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL10929500 | 0.86 | USP2 (0.65) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL10930823 | 0.86 | USP2 (0.65) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL10929495 | 0.86 | USP2 (0.65) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL16926435 | 0.85 | CYP46A1 (0.69) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL17129625 | 0.85 | CYP46A1 (0.69) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL10622619 | 0.85 | CYP46A1 (0.69) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL20470662 | 0.85 | CYP46A1 (0.69) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL16299806 | 0.85 | CYP46A1 (0.69) | CYP46A1USP2LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10520 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313818-A1 | CRISPR-Cas Effector Polypeptides and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-10-09 | — | — | US | claimed |
| US-12215343-B2 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-04 | — | — | US | claimed |
| EP-3419665-B1 | TREATMENT METHODS FOR FIBROSIS TARGETING SMOC2 | BRIGHAM & WOMENS HOSPITAL INC (US) | 2024-10-30 | — | — | EP | claimed |
| US-12123015-B2 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-10-22 | — | — | US | claimed |
| US-20240229029-A9 | COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-11 | — | — | US | claimed |
| US-20240141348-A1 | ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-02 | — | — | US | claimed |
| US-11970711-B2 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-30 | — | — | US | claimed |
| US-20240132889-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-25 | — | — | US | claimed |
| WO-2023201203-A2 | CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-19 | — | — | WO | claimed |
| US-11674159-B2 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-13 | — | — | US | claimed |
| US-20020039741-A1 | Antitumor agent | DEAN NICHOLAS M (US) | 2002-04-04 | — | — | US | claimed |
| EP-0957926-A4 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS INC (US) | 2002-01-23 | — | — | EP | claimed |
| US-6319906-B1 | FOR THERAPY OF AUTOIMMUNE DISEASE, INFLAMMATORY DISEASE, FOR INHIBITING ALLOGRAFT REJECTION | ISIS PHARMACEUTICALS | 2001-11-20 | — | — | US | claimed |
| US-6312900-B1 | FOR MODULATING METASTASIS OF MALIGNANT TUMORS VIA MODULATION OF ACTIVATING PROTEIN 1 | ISIS PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | claimed |
| JP-2000507833-A | — | — | 2000-06-27 | — | — | JP | claimed |
| US-6077833-A | FOR DIAGNOSIS, PREVENTION AND TREATMENT OF IMMUNE STATES AND DISORDERS AMENABLE TO TREATMENT THROUGH MODULATION OF T CELL ACTIVATION SUCH AS FOR PREVENTING ALLOGRAFT REJECTION | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-20 | — | — | US | claimed |
| US-6001991-A | NUCLEOTIDE SEQUENCES WHICH HYBRIDIZE TO AND SUPPRESS EXPRESSION OF MULTIDRUG RESISTANCE GENE; FOR PREVENTING OR MODULATING THE DEVELOPMENT OF MULTIDRUG RESISTANCE DURING CHEMOTHERAPEUTIC TREATMENT OR RESENSITIZING TREATED CELLS | ISIS PHARMACEUTICALS INC. (US) | 1999-12-14 | — | — | US | claimed |
| EP-0957926-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 1999-11-24 | — | — | EP | claimed |
| WO-1998029124-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | claimed |
| WO-1998014615-A1 | ANTISENSE OLIGONUCLEOTIDE MODULATION OF MDR P-GLYCOPROTEIN GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1998-04-09 | — | — | WO | claimed |